Market Place
Sourcing Support
Celldex Doses First Patient In Phase 1 Study Of CDX-622
20 Nov 2024 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at Upcoming Investor Conferences
11 Nov 2024 //
GLOBENEWSWIRE
Celldex drops phase 1 tumor bispecific to focus on inflammation
08 Nov 2024 //
FIERCE BIOTECH
Celldex Reports Q3 2024 Financials & Corporate Updates
06 Nov 2024 //
GLOBENEWSWIRE
Celldex to Present 12-Week Barzolvolimab Results at ACAAI 2024
25 Oct 2024 //
GLOBENEWSWIRE
Celldex Presents Barzolvolimab Results At EADV 2024
25 Sep 2024 //
GLOBENEWSWIRE
Celldex Announces Barzolvolimab Data Presentation At EADV
16 Sep 2024 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at Upcoming Investor Conferences
12 Sep 2024 //
GLOBENEWSWIRE
Celldex Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Celldex`s Anti-cKIT Antibody Reduces Chronic Hives In Phase 2 Trial
30 Jul 2024 //
FIERCE BIOTECH
Celldex Reports Positive Phase 2 Results For Barzolvolimab In Urticaria
29 Jul 2024 //
GLOBENEWSWIRE
Celldex Initiates Phase 3 Program For Barzolvolimab In Urticaria
16 Jul 2024 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at Jefferies Healthcare Conference
04 Jun 2024 //
GLOBENEWSWIRE
Barzolvolimab Shows Angioedema Improvements In Chronic Urticaria At EAACI
02 Jun 2024 //
GLOBENEWSWIRE
Celldex Doses First Patient In Barzolvolimab Prurigo Nodularis Phase 2 Study
15 May 2024 //
GLOBENEWSWIRE
Celldex Reports Q1 2024 Results, Corporate Update
06 May 2024 //
GLOBENEWSWIRE
Celldex to Participate in the Leerink Partners Global Biopharma Conference
08 Mar 2024 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
05 Mar 2024 //
YAHOO FINANCE
Celldex Therapeutics Announces Closing of Public Offering of Common Stock
05 Mar 2024 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at TD Cowens 44th Annual Health Care Conference
05 Mar 2024 //
GLOBENEWSWIRE
Celldex Announces Pricing of Upsized $400M Public Offering of Common Stock
29 Feb 2024 //
PRESS RELEASE
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
28 Feb 2024 //
GLOBENEWSWIRE
Celldex’s CSU drug could challenge a Novartis candidate after PhII
27 Feb 2024 //
ENDPTS
Celldex Reports Fourth Quarter and Year End 2023 Financial Results
26 Feb 2024 //
GLOBENEWSWIRE
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab
24 Feb 2024 //
GLOBENEWSWIRE
Celldex to Participate in Guggenheim Healthcare Talks 6th Annual Conference
06 Feb 2024 //
GLOBENEWSWIRE
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results
05 Feb 2024 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
27 Nov 2023 //
GLOBENEWSWIRE
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
07 Nov 2023 //
GLOBENEWSWIRE
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
07 Nov 2023 //
GLOBENEWSWIRE
Celldex Therapeutics Announces Positive Results from Barzolvolimab Phase 2 Study
06 Nov 2023 //
PRESS RELEASE
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab
06 Nov 2023 //
GLOBENEWSWIRE
Celldex laces up next to Big Pharmas with chronic hive drug
06 Nov 2023 //
FIERCE BIOTECH
Celldex Presents Data from Prurigo Nodularis Phase 1b Study of Barzolvolimab
05 Nov 2023 //
GLOBENEWSWIRE
Celldex Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results
26 Sep 2023 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
25 Sep 2023 //
GLOBENEWSWIRE
Celldex Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab
11 Jul 2023 //
GLOBENEWSWIRE
Celldex Announces First Patient Dosed in Ph2 Study of Barzolvolimab
06 Jul 2023 //
GLOBENEWSWIRE
Celldex Presents Data from Barzolvolimab Chronic Urticaria Program at EAACI
10 Jun 2023 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585
31 May 2023 //
GLOBENEWSWIRE
Celldex Presents +ve Preclinical Data from TSLP/SCF Bispecific Antibody
15 May 2023 //
GLOBENEWSWIRE
Celldex Reports 1Q FYR 2023 and Provides Corporate Update
04 May 2023 //
GLOBENEWSWIRE
Celldex to Present at H.C. Wainwright Autoimmune Virtual Conference
29 Mar 2023 //
GLOBENEWSWIRE
Celldex Reports Fourth Quarter and Year End 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Celldex fleshes out case for Xolair challenger in chronic hives
28 Feb 2023 //
ENDPTS
Celldex Therapeutics Announces Appointment of Rita Jain to Board of Directors
16 Feb 2023 //
GLOBENEWSWIRE
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
15 Feb 2023 //
GLOBENEWSWIRE
Celldex Announces Presentation of Barzolvolimab P1b Results
03 Feb 2023 //
GLOBENEWSWIRE
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study
06 Dec 2022 //
GLOBENEWSWIRE
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab
02 Dec 2022 //
GLOBENEWSWIRE
Celldex to Participate in Upcoming November Investor Conferences
10 Nov 2022 //
GLOBENEWSWIRE
Celldex Reports 3Q 2022 Financial Results and Provides Corporate Update
09 Nov 2022 //
GLOBENEWSWIRE
Research Analysts Offer Predictions for Celldex, Q3 2022 Earnings
13 Oct 2022 //
MARKETBEAT
Celldex Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab
21 Jul 2022 //
GLOBENEWSWIRE
Celldex offers a positive early readout for their rival drug
01 Jul 2022 //
ENDPTS
Celldex Tx Presents Positive Interim Data from Barzolvolimab PIb Study in CSU
30 Jun 2022 //
GLOBENEWSWIRE
